Lebrikizumab

Lebrikizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	IL-13
Clinical data
Trade names	Ebglyss
Other names	MILR1444A, RG3637, TNX-650, lebrikizumab-lbkz
AHFS/Drugs.com	Monograph
MedlinePlus	a624064
License data	US DailyMed: Lebrikizumab;
Pregnancy; category	AU: B1;
Routes of; administration	Subcutaneous
ATC code	D11AH10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	953400-68-5 ;
DrugBank	DB11914 ;
ChemSpider	none;
UNII	U9JLP7V031;
KEGG	D09633 ;
Chemical and physical data
Formula	C6434H9972N1700O2034S50
Molar mass	145287.42 g·mol−1
	(what is this?) (verify)

Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin-13 antagonist. It is given by subcutaneous injection.

The most common side effects include injection site reactions, dry eye and conjunctivitis (redness and discomfort in the eye) including allergic conjunctivitis.

Lebrikizumab was approved for medical use in the European Union in November 2023, in Canada in June 2024, and in the United States in September 2024.